Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sequential or Concurrent Administration of Trastuzumab in Early Breast Cancer? Too Early to Judge

(2010) Hatem A. Azim et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

(2009) Marc Spielmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

(2008) S. Dawood et al.   ANNALS OF ONCOLOGY

Jumping higher: is it still possible? The ALTTO trial challenge

(2008) Gianluca Tomasello et al.   Expert Review of Anticancer Therapy

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY

Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2008) I. J. Dahabreh et al.   ONCOLOGIST